{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:12:03Z","timestamp":1794859923126,"version":"4.9.1"},"reference-count":59,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial\/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record\u2013derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre\u2013novel therapy era (Pre era; 2014-2018; n\u00a0=\u00a02998) or post\u2013novel therapy era (Post era; 2019-2022; n\u00a0=\u00a02098). Patients in the Post era were older and had more comorbidities than Pre era. Non-Hispanic Black (NHB) and Hispanic patients were younger and more likely to have lower socioeconomic status than non-Hispanic White (NHW) patients, with no differences in the distributions of key disease features. After accounting for age and comorbidity, overall survival (OS) was higher in patients in Post era than Pre era (adjusted hazard ratio [aHR], 0.90; 95% confidence interval [CI], 0.83-0.96). In Pre era, NHB had a 22% higher hazard of death than NHW (aHR,\u00a01.22; 95%\u00a0CI,\u00a01.04-1.43), whereas worse OS was not observed for NHB in Post era (aHR,\u00a00.86; 95%\u00a0CI,\u00a00.69-1.08; predicted 2-year survival,\u00a045.3% vs 39.9%). Utilization of novel therapeutics in frontline therapy did not differ by race\/ethnicity. Among patients receiving\u00a0venetoclax-based induction, particularly those without TP53, RAS, or FLT3-ITD mutations, results suggested higher OS for NHB than NHW patients (aHR,\u00a00.67; 95%\u00a0CI,\u00a00.45-1.01). Additional studies are needed to elucidate factors contributing to these observed survival differences and to inform strategies to optimize outcomes for all patients with AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014127","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:31:01Z","timestamp":1738323061000},"page":"533-544","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Evolving racial\/ethnic disparities in AML survival in the novel therapy era"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-3098","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"2Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-9799","authenticated-orcid":false,"given":"Phyllis A.","family":"Gimotty","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-3998","authenticated-orcid":false,"given":"Andrew H.","family":"Matthews","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria V.","family":"Babushok","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R.","family":"McCurdy","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena Jordan","family":"Bruno","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Gill","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-951X","authenticated-orcid":false,"given":"Vikram R.","family":"Paralkar","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1312-6748","authenticated-orcid":false,"given":"Ivan","family":"Maillard","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W.","family":"Pratz","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Getz","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-0281","authenticated-orcid":false,"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"2","key":"2025032119365015900_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"issue":"15","key":"2025032119365015900_bib2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2025032119365015900_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1055-9965.EPI-14-0963","article-title":"How do differences in treatment impact racial and ethnic disparities in acute myeloid leukemia?","volume":"24","author":"Patel","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"2025032119365015900_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/COC.0b013e31828d7536","article-title":"Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?","volume":"38","author":"Patel","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"2025032119365015900_bib5","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2003-09-3118","article-title":"Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia","volume":"103","author":"Sekeres","year":"2004","journal-title":"Blood"},{"issue":"16 suppl","key":"2025032119365015900_bib6","doi-asserted-by":"crossref","first-page":"e19007","DOI":"10.1200\/JCO.2022.40.16_suppl.e19007","article-title":"Racial disparities in patients with TP53 mutated acute myeloid leukemia","volume":"40","author":"Badar","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025032119365015900_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.leukres.2014.04.001","article-title":"Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis","volume":"38","author":"Brunner","year":"2014","journal-title":"Leuk Res"},{"issue":"19","key":"2025032119365015900_bib8","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1182\/bloodadvances.2022007544","article-title":"High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML","volume":"6","author":"Larkin","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025032119365015900_bib9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41598-017-19081-4","article-title":"Racial differences in four leukemia subtypes: comprehensive descriptive epidemiology","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"2025032119365015900_bib10","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s10552-012-0062-3","article-title":"Understanding disparities in leukemia: a national study","volume":"23","author":"Patel","year":"2012","journal-title":"Cancer Causes Control"},{"key":"2025032119365015900_bib11","doi-asserted-by":"crossref","first-page":"n2026","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"2025032119365015900_bib12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"issue":"9","key":"2025032119365015900_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"Dohner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2025032119365015900_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends in Pharmacological Science"},{"key":"2025032119365015900_bib15","author":"Administration USFD","year":"2018"},{"issue":"7","key":"2025032119365015900_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032119365015900_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40487-023-00229-4","article-title":"Diagnostic and treatment obstacles in acute myeloid leukemia: social, operational, and financial","volume":"11","author":"Gen\u00e7","year":"2023","journal-title":"Oncol Ther"},{"issue":"12","key":"2025032119365015900_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an International Expert Panel","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2025032119365015900_bib19","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood.2021012830","article-title":"Structural racism is a mediator of disparities in acute myeloid leukemia outcomes","volume":"139","author":"Abraham","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025032119365015900_bib20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1056\/NEJMms2025396","article-title":"How structural racism works \u2014 racist policies as a root cause of U.S. racial health inequities","volume":"384","author":"Bailey","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9596","key":"2025032119365015900_bib21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"2025032119365015900_bib22","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"7  2023","journal-title":"medRxiv"},{"key":"2025032119365015900_bib23","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2001.09765","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"13  2020","journal-title":"arXiv"},{"issue":"4","key":"2025032119365015900_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2025032119365015900_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"6","key":"2025032119365015900_bib26","first-page":"1787","article-title":"The tale wagged by the DAG: broadening the scope of causal inference and explanation for epidemiology","volume":"45","author":"Krieger","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"12","key":"2025032119365015900_bib27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025032119365015900_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1536867X1101100104","article-title":"Pointwise confidence intervals for the covariate-adjusted survivor function in the Cox model","volume":"11","author":"Cefalu","year":"2011","journal-title":"STATA J"},{"key":"2025032119365015900_bib29","author":"Marubini","year":"2004"},{"issue":"2","key":"2025032119365015900_bib30","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/EDE.0000000000000253","article-title":"SAS macro for causal mediation analysis with survival data","volume":"26","author":"Valeri","year":"2015","journal-title":"Epidemiology"},{"issue":"4","key":"2025032119365015900_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/EDE.0b013e31821c680c","article-title":"Direct and indirect effects in a survival context","volume":"22","author":"Lange","year":"2011","journal-title":"Epidemiology"},{"issue":"4","key":"2025032119365015900_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/EDE.0b013e31821db37e","article-title":"Causal mediation analysis with survival data","volume":"22","author":"VanderWeele","year":"2011","journal-title":"Epidemiology"},{"key":"2025032119365015900_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","article-title":"Mediation analysis: a practitioner's guide","volume":"37","author":"VanderWeele","year":"2016","journal-title":"Annu Rev Public Health"},{"issue":"5","key":"2025032119365015900_bib34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/EDE.0000000000000121","article-title":"A\u00a0unification of mediation and interaction: a 4-way decomposition","volume":"25","author":"VanderWeele","year":"2014","journal-title":"Epidemiology"},{"issue":"2","key":"2025032119365015900_bib35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/EDE.0b013e318281a64e","article-title":"A\u00a0three-way decomposition of a total effect into direct, indirect, and interactive effects","volume":"24","author":"VanderWeele","year":"2013","journal-title":"Epidemiology"},{"key":"2025032119365015900_bib36","author":"StataCorp","year":"2021"},{"issue":"9","key":"2025032119365015900_bib37","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025032119365015900_bib38","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2025032119365015900_bib39","first-page":"68","article-title":"Gemtuzumab ozogamicin: back again","volume":"10","author":"Selby","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"7","key":"2025032119365015900_bib40","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A\u00a0modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"suppl 1","key":"2025032119365015900_bib41","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025032119365015900_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2025032119365015900_bib43","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","article-title":"Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"},{"issue":"13","key":"2025032119365015900_bib44","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025032119365015900_bib45","article-title":"Analysis of elderly patients (\u226570 years old) with acute leukemia in the era of targeted therapy","volume":"134","author":"Rozental","year":"2019","journal-title":"Blood"},{"key":"2025032119365015900_bib46","first-page":"2819372","article-title":"Socioeconomic and racial\/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities","volume":"2017","author":"Singh","year":"2017","journal-title":"J\u00a0Environ Public Health"},{"issue":"suppl 1","key":"2025032119365015900_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2019-130978","article-title":"Area-based socioeconomic disparities in survival of children with newly diagnosed acute myeloid leukemia: a report from the Children's Oncology Group","volume":"134","author":"Winestone","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119365015900_bib48","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2023-181244","article-title":"Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"142","author":"Olivieri","year":"2023","journal-title":"Blood"},{"issue":"S16","key":"2025032119365015900_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.COT.0000789448.70830.ac","article-title":"Exploring racial & ethnic enrollment disparities in AML clinical trials","volume":"43","author":"Nalley","year":"2021","journal-title":"Oncol Times"},{"issue":"21","key":"2025032119365015900_bib50","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1182\/bloodadvances.2021005148","article-title":"Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials","volume":"5","author":"Hantel","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2025032119365015900_bib51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/2159-8290.CD-20-1579","article-title":"Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia","volume":"11","author":"Bhatnagar","year":"2021","journal-title":"Cancer Discov"},{"key":"2025032119365015900_bib52","doi-asserted-by":"crossref","first-page":"107354","DOI":"10.1016\/j.leukres.2023.107354","article-title":"Changing frontline AML treatment patterns from 2013 to 2022","volume":"132","author":"Brandwein","year":"2023","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"2025032119365015900_bib53","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood-2023-189963","article-title":"Treatment patterns and outcomes of patients with acute myeloid leukemia (AML) from 2013 to 2022: a Connect \u00ae Myeloid Registry Study","volume":"142","author":"Grinblatt","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025032119365015900_bib54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.33873","article-title":"Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: a population-based analysis in the modern era","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"2025032119365015900_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2025032119365015900_bib56","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119365015900_bib57","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2023-181876","article-title":"Genomic profiles and associated survival prognosticators in Black patients with acute myeloid leukemia","volume":"142","author":"Stiff","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025032119365015900_bib58","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2025032119365015900_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41512-020-00077-0","article-title":"Informative missingness in electronic health record systems: the curse of knowing","volume":"4","author":"Groenwold","year":"2020","journal-title":"Diagn Progn Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/533\/2353905\/blooda_adv-2024-014127-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/533\/2353905\/blooda_adv-2024-014127-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T16:06:59Z","timestamp":1742573219000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/3\/533\/535329\/Evolving-racial-ethnic-disparities-in-AML-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014127","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}